Double blinded, randomized, Priorix- and placebo-controlled, trial to evaluate the optimal dose of MV-CHIK vaccine (against Chikungunya virus) in regard to immunogenicity, safety and tolerability in healthy volunteers.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Oct 2017
At a glance
- Drugs Chikungunya virus vaccine (Primary) ; Measles mumps and rubella virus vaccine-(Priorix)
- Indications Chikungunya virus infections
- Focus Pharmacodynamics
- Sponsors Themis Bioscience
- 10 Oct 2017 Planned End Date changed from 1 Aug 2017 to 1 Jun 2018.
- 10 Oct 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Mar 2018.
- 10 Oct 2017 Status changed from recruiting to active, no longer recruiting.